Live Breaking News & Updates on இம்‌ஸ்|Page 5

Stay updated with breaking news from இம்‌ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lockheed in discussions with government to finalize F-35 deliveries for 2022


Message :
Required fields
(Reuters) - Lockheed Martin Corp, which aims to produce 169 F-35 fighter jets in 2022, is in discussions with the U.S. government to finalize total aircraft deliveries and production rate for the year, the company said in a statement.
While initial discussions indicated 169 aircraft in 2022, we will provide a production range when finalized, the U.S. weapons maker said.   
The U.S. government is Lockheed s biggest customer, accounting for three quarters of its sales last year.
Lockheed provided an estimate about its F-35 producti
on plans at a conference hosted by brokerage Bernstein earlier this week. https://reut.rs/2SaueFF ....

Ankit Ajmera , Shinjini Ganguli , Lockheed Martin Corporation Stock Exchange , Press Release , He Lmt Us5398301094 , அங்கித் அஜ்மேற , ஷின்ஜினி கங்குலி , லாக்ஹீட் மார்டின் நிறுவனம் ஸ்டாக் பரிமாற்றம் ,

Ørsted aims for net - positive biodiversity impact from new projects commissioned from 2030

New challenges to be solved Today, Ørsted works to avoid, mitigate, and address the potential . which are more dynamic and variable due to the forces of . ....

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors


Message :
Required fields
Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy
First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-small cell lung cancer (NSCLC)
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the first patient had been dosed in the Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy (RT). This triple combination is actively recruiting at The University of Texas MD Anderson Cancer Center, with Dr. Vivek Subbiah as principal investigator, in seven metastatic or locally advanc ....

New York , United States , Vivek Subbiah , Ashleyr Robinson , Ramon Mohanlal , Darren Opland , Lifesci Advisors , Lifesci Communications , University Of Texas Md Anderson Cancer Center , Beyondspring The Company Or , Cancer Center , Select Advanced Malignancies , Cancer Poster Session , Like Macrophage Polarization , Anti Tumor Immunity , New York City , Sci Advisors , Beyondspring Inc Stock Exchange , Press Release , Eytruda Bysi Kyg108301006 , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , விவேக் சுப்பையா , ராமன் மோகன்லால் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , புற்றுநோய் மையம் ,